Mouse Genome Informatics
cn
    Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Trp53tm1Brd/Trp53+

involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
endocrine/exocrine glands
• mutants exhibit increased mammary epithelial cellular proliferation compared to controls when treated with exogenous estrogen (J:132088)
• mutants exposed to estrogen exhibit an increase in the number of hyperplastic alveolar nodules per mammary gland compared to mutants with wild-type Trp53 and also an increase in the percentage of mice with hyperplastic alveolar nodules (J:132088)

tumorigenesis
• 25% of mutants develop invasive mammary cancer when exposed to exogenous estrogen
• cancers are Esr1-negative
• mutants develop mammary gland preneoplasia that are Esr1-negative

renal/urinary system
• 25% of mutants develop ureteral obstruction 1-3 months after estrogen pellet placement

integument
• mutants exhibit increased mammary epithelial cellular proliferation compared to controls when treated with exogenous estrogen (J:132088)
• mutants exposed to estrogen exhibit an increase in the number of hyperplastic alveolar nodules per mammary gland compared to mutants with wild-type Trp53 and also an increase in the percentage of mice with hyperplastic alveolar nodules (J:132088)

cellular
• mutants exhibit increased mammary epithelial cellular proliferation compared to controls when treated with exogenous estrogen (J:132088)

Mouse Models of Human Disease
OMIM IDRef(s)
Breast-Ovarian Cancer, Familial, Susceptibility to, 1; BROVCA1 604370 J:132088